Milestone Payments was Xenon Pharmaceuticals’s largest revenue line in fiscal 2017, bringing in $250.00K of $309.00K (81%).
| Type Of Arrangement | FY 2014 | FY 2015 | FY 2016 | FY 2017 |
|---|---|---|---|---|
| Recognition Of Upfront Payment | — | $10.90M | $157.00K | — |
| Recognition Of Upfront Payments | $12.26M | — | — | — |
| Milestone Payments | $7.91M | $250.00K | — | $250.00K |
| Research Funding | $4.25M | $3.59M | $1.49M | $59.00K |
| Total | $24.42M | $14.74M | $1.65M | $309.00K |
Xenon Pharmaceuticals brought in $309.00K from its two revenue lines in fiscal 2017, the year ended December 31, 2017. Xenon Pharmaceuticals regrouped these revenue lines after fiscal 2016, so the total does not compare directly with that year's $1.65M. Milestone Payments was the largest at $250.00K (80.9%), ahead of Research Funding at $59.00K (19.1%).
Xenon Pharmaceuticals stopped reporting Recognition Of Upfront Payments ($12.26M in fiscal 2014) and Recognition Of Upfront Payment ($157.00K in fiscal 2016) as separate revenue lines.
Xenon Pharmaceuticals (XENE) reports its revenue by type of arrangement. In fiscal 2017, Milestone Payments was its largest revenue line, bringing in $250.00K (80.9% of the total), followed by Research Funding at $59.00K (19.1%).
Milestone Payments was Xenon Pharmaceuticals' largest revenue line in fiscal 2017, bringing in $250.00K, or 80.9% of the $309.00K total across its two revenue lines.
Every figure comes from Xenon Pharmaceuticals' annual financial filings, as reported. Each line keeps the name Xenon Pharmaceuticals gives it, and years follow its fiscal calendar.
Xenon Pharmaceuticals' revenue by type of arrangement goes back to fiscal 2014, with figures through fiscal 2017. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.